Comparative Pharmacology
Head-to-head clinical analysis: PANCREAZE versus ZENPEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANCREAZE versus ZENPEP.
PANCREAZE vs ZENPEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pancreatic enzyme replacement therapy; provides lipase, amylase, and protease to digest fats, carbohydrates, and proteins in the duodenum, compensating for pancreatic exocrine insufficiency.
ZenPep (pancrelipase) is a pancreatic enzyme replacement therapy containing lipase, protease, and amylase. It hydrolyzes fats to monoglycerides, glycerol, and fatty acids; proteins to amino acids and peptides; and starch to dextrins and short-chain sugars, thereby facilitating digestion in patients with exocrine pancreatic insufficiency.
500 to 2500 lipase units/kg per meal, orally, typically 25000 to 75000 lipase units per meal.
500 lipase units/kg per meal orally, with snacks at half the meal dose; maximum 2500 lipase units/kg per meal or 10,000 lipase units/kg per day.
None Documented
None Documented
Not applicable; as a locally acting enzyme, systemic half-life is not relevant. Enzymes are degraded in the GI tract and excreted in feces.
Not applicable; ZenPep is not absorbed systemically and has no measurable plasma half-life. Clinical effect is directly related to local enzyme activity in the duodenum.
Not applicable; PANCREAZE (pancrelipase) is a digestive enzyme replacement. It works locally in the gastrointestinal tract and is not absorbed systemically. Elimination occurs via fecal excretion of undigested enzymes and breakdown products.
ZenPep (pancrelipase) is not absorbed systemically; it acts locally in the gastrointestinal tract. No significant systemic absorption occurs; therefore, excretion is primarily fecal as unabsorbed enzymes and degradation products. Renal excretion is negligible.
Category C
Category C
Pancreatic Enzyme Replacement
Pancreatic Enzyme Replacement